Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa
In 2011, South Africa implemented a policy to decentralize treatment for rifampin-resistant tuberculosis (TB) to reduce durations of hospitalization and enable local treatment. We assessed policy implementation in Western Cape Province, where services expanded from 6 specialized TB hospitals to 406 facilities, by analyzing National Health Laboratory Service data on TB during 2012-2015. We calculated the percentage of patients who visited a TB hospital <1 year after rifampin-resistant TB diagnosis, the median duration of their hospitalizations, and the total distance between facilities visited. We assessed temporal changes with linear regression and stratified results by location. Of 2,878 patients, 65% were from Cape Town. In Cape Town, 29% visited a TB hospital; elsewhere, 68% visited a TB hospital. We found that hospitalizations and travel distances were shorter in Cape Town than in the surrounding areas.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 27(2021), 3 vom: 24., Seite 728-739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leavitt, Sarah V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.07.2021 Date Revised 20.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2703.203204 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32180807X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32180807X | ||
| 003 | DE-627 | ||
| 005 | 20231225180658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2703.203204 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM32180807X | ||
| 035 | |a (NLM)33622466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leavitt, Sarah V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2021 | ||
| 500 | |a Date Revised 20.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In 2011, South Africa implemented a policy to decentralize treatment for rifampin-resistant tuberculosis (TB) to reduce durations of hospitalization and enable local treatment. We assessed policy implementation in Western Cape Province, where services expanded from 6 specialized TB hospitals to 406 facilities, by analyzing National Health Laboratory Service data on TB during 2012-2015. We calculated the percentage of patients who visited a TB hospital <1 year after rifampin-resistant TB diagnosis, the median duration of their hospitalizations, and the total distance between facilities visited. We assessed temporal changes with linear regression and stratified results by location. Of 2,878 patients, 65% were from Cape Town. In Cape Town, 29% visited a TB hospital; elsewhere, 68% visited a TB hospital. We found that hospitalizations and travel distances were shorter in Cape Town than in the surrounding areas | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a South Africa | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a bacteria | |
| 650 | 4 | |a decentralized care | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a health policy | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a rifampin | |
| 650 | 4 | |a rifampin-resistant | |
| 650 | 4 | |a routinely collected data | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a tuberculosis | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 700 | 1 | |a Jacobson, Karen R |e verfasserin |4 aut | |
| 700 | 1 | |a Ragan, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Bor, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Bouton, Tara C |e verfasserin |4 aut | |
| 700 | 1 | |a Dolby, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Warren, Robin M |e verfasserin |4 aut | |
| 700 | 1 | |a Jenkins, Helen E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 27(2021), 3 vom: 24., Seite 728-739 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:3 |g day:24 |g pages:728-739 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2703.203204 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 3 |b 24 |h 728-739 | ||